1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment SBIR (R43/R44) is sponsored by National Institute on Drug Abuse (NIDA). This funding opportunity targets the development of field-deployable, low-cost point-of-need approaches and technologies to reduce barriers to SUD diagnosis and treatment.
Get alerted about grants like this
Get emailed when new opportunities from “National Institute on Drug Abuse (NIDA)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R43/R44 Clinical Trial Optional) - Federal Grant Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R43/R44 Clinical Trial Optional) The summary for the Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R43/R44 Clinical Trial Optional) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants. com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact .
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R43/R44 Clinical Trial Optional): The FOA intends to spur the development of cost-effective technologies that may reduce or even eliminate disparities in SUD treatment.
Disparities due to geographical access or rural/urban divide, due to treatment cost, or due to stigma will be specifically targeted. The intention is to bring to the treatment to the patient, not the patient to the treatment.
Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R43/R44 Clinical Trial Optional) National Institutes of Health (HHS-NIH11) Funding Opportunity Number: Current Application Deadline: Original Application Deadline: Maximum Federal Grant Award: Minimum Federal Grant Award: Expected Number of Awards: Cost Sharing or Matching: Applicants Eligible for this Grant Additional Information on Eligibility Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. See full Notice of Funding Opportunity for additional details on eligibility.
Link to Full Grant Announcement https://grants. nih. gov/grants/guide/rfa-files/RFA-DA-24-018.
html Grant Announcement Contact See Section VII. Agency Contacts within the full opportunity announcement for all other inquires. Similar Government Grants • Limited Competition: Growing Great Ideas: Research Education Course in Entrepreneurship an...
• Science Track Award for Research Transition (START) Program (R03, Clinical Trial Optional) • Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on H... • Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeu... • CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R01 Clinical...
• NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards • Drug Abuse Aspects of Hiv/Aids and Other Infections • Epidemiology of Drug Abuse More Grants from the National Institutes of Health • Research Centers in Minority Institutions (RCMI) Coordinating Center (U24 - Clinical Trial... • Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VC...
• Nutrition Obesity Research Centers (NORCs) (P30 Clinical Trial Optional) • Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal ... • PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine... Federal Grants by Category Grants for Single Mothers Small Business Grants for Women Federal Grants for College Federal Tuition Assistance
According to the current listing, eligibility includes: Small business concerns (SBC) are eligible. Confirm the full requirements in the official notice before applying.
The current listing shows budgets up to $306,872 total costs for Phase I and up to $2,045,816 total costs for Phase II. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment SBIR (R43/R44) is funded by National Institute on Drug Abuse (NIDA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H's FASTPASS program targets a public-health blind spot: substandard and contaminated drugs that are only caught after patients are exposed. It funds through-package chemical sensing (TA1 SAMPLE) and the analytics to act on it (TA2 DETECT). The solicitation posts to SAM.gov in mid-August 2026, with a virtual Proposer Workshop on August 24 and registration closing August 20. Here is what FASTPASS funds, why the timing matters, and how to position a cross-disciplinary team.
Read articleARPA-H PROSPR program funds seven research teams testing rapamycin, semaglutide, and novel compounds to extend healthspan. A deep analysis of the science, the money, and what it means for the field.
Read article